PHARVARIS NV

Pharvaris NV insider Abele Stefan Andreas now holds 49,216 shares after a 3/A filing, signaling executive confidence amid Phase 3 clinical progress and value‑based care trends.

Pharvaris NV insider holdings reveal confidence in its oral B2 antagonist launch, payer talks, and phased option vesting—highlighting low agency risk and upside potential for investors.